Global Levodopa API Market Growth 2025-2031

Publication ID:

LPI08251862

Publication Date:

August 4, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Levodopa API market size is predicted to grow from US$ 131 million in 2025 to US$ 197 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Levodopa, also known as L-DOPA, is an API (Active Pharmaceutical Ingredient) used primarily in the treatment of Parkinson's disease. It's a precursor to dopamine, a neurotransmitter that is deficient in the brains of people with Parkinson's. Levodopa is converted into dopamine in the brain, helping to alleviate the motor symptoms associated with the disease, such as tremors, stiffness, and slow movements.
Levodopa has a unique pharmacological mechanism and is the mainstream drug for the treatment of Parkinson's disease. Parkinson's disease (PD) prevalence and incidence are generally increasing globally, driven by an aging population and improved diagnostic capabilities. While some regions may show declining trends in incidence, the overall burden of PD is expected to continue rising. This increase is particularly noticeable in older age groups and among men. Dopamine replacement therapy based on levodopa is still regarded as the "gold standard" for PD treatment. Against the backdrop of long-term growth in the Parkinson's disease drug market, the market size of levodopa as a mainstream drug will continue to grow.
The 鈥淟evodopa API Industry Forecast鈥� looks at past sales and reviews total world Levodopa API sales in 2024, providing a comprehensive analysis by region and market sector of projected Levodopa API sales for 2025 through 2031. With Levodopa API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Levodopa API industry.
This Insight Report provides a comprehensive analysis of the global Levodopa API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Levodopa API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Levodopa API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Levodopa API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Levodopa API.
This report presents a comprehensive overview, market shares, and growth opportunities of Levodopa API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Purity: 鈮�98%
笔耻谤颈迟测:鈮�99%
Segmentation by Application:
Oral Preparations
Injectable Preparations
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Shandong Xinhua Pharmaceutical
Zhejiang Wild Wind Pharmaceutical
Zhe JIANG HUA HAI Pharmaceutical
Divi's Laboratories
Amino Sciences
Alfa Chemistry
Chuxiong Yunzhi Phytopharmaceutical
Bei Jing Scrianen Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Levodopa API market?
What factors are driving Levodopa API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Levodopa API market opportunities vary by end market size?
How does Levodopa API break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Levodopa API Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Levodopa API by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Levodopa API by Country/Region, 2020, 2024 & 2031
2.2 Levodopa API Segment by Type
2.2.1 Purity: 鈮�98%
2.2.2 笔耻谤颈迟测:鈮�99%
2.3 Levodopa API Sales by Type
2.3.1 Global Levodopa API Sales Market Share by Type (2020-2025)
2.3.2 Global Levodopa API Revenue and Market Share by Type (2020-2025)
2.3.3 Global Levodopa API Sale Price by Type (2020-2025)
2.4 Levodopa API Segment by Application
2.4.1 Oral Preparations
2.4.2 Injectable Preparations
2.5 Levodopa API Sales by Application
2.5.1 Global Levodopa API Sale Market Share by Application (2020-2025)
2.5.2 Global Levodopa API Revenue and Market Share by Application (2020-2025)
2.5.3 Global Levodopa API Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Levodopa API Breakdown Data by Company
3.1.1 Global Levodopa API Annual Sales by Company (2020-2025)
3.1.2 Global Levodopa API Sales Market Share by Company (2020-2025)
3.2 Global Levodopa API Annual Revenue by Company (2020-2025)
3.2.1 Global Levodopa API Revenue by Company (2020-2025)
3.2.2 Global Levodopa API Revenue Market Share by Company (2020-2025)
3.3 Global Levodopa API Sale Price by Company
3.4 Key Manufacturers Levodopa API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Levodopa API Product Location Distribution
3.4.2 Players Levodopa API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Levodopa API by Geographic Region
4.1 World Historic Levodopa API Market Size by Geographic Region (2020-2025)
4.1.1 Global Levodopa API Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Levodopa API Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Levodopa API Market Size by Country/Region (2020-2025)
4.2.1 Global Levodopa API Annual Sales by Country/Region (2020-2025)
4.2.2 Global Levodopa API Annual Revenue by Country/Region (2020-2025)
4.3 Americas Levodopa API Sales Growth
4.4 APAC Levodopa API Sales Growth
4.5 Europe Levodopa API Sales Growth
4.6 Middle East & Africa Levodopa API Sales Growth
5 Americas
5.1 Americas Levodopa API Sales by Country
5.1.1 Americas Levodopa API Sales by Country (2020-2025)
5.1.2 Americas Levodopa API Revenue by Country (2020-2025)
5.2 Americas Levodopa API Sales by Type (2020-2025)
5.3 Americas Levodopa API Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Levodopa API Sales by Region
6.1.1 APAC Levodopa API Sales by Region (2020-2025)
6.1.2 APAC Levodopa API Revenue by Region (2020-2025)
6.2 APAC Levodopa API Sales by Type (2020-2025)
6.3 APAC Levodopa API Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Levodopa API by Country
7.1.1 Europe Levodopa API Sales by Country (2020-2025)
7.1.2 Europe Levodopa API Revenue by Country (2020-2025)
7.2 Europe Levodopa API Sales by Type (2020-2025)
7.3 Europe Levodopa API Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Levodopa API by Country
8.1.1 Middle East & Africa Levodopa API Sales by Country (2020-2025)
8.1.2 Middle East & Africa Levodopa API Revenue by Country (2020-2025)
8.2 Middle East & Africa Levodopa API Sales by Type (2020-2025)
8.3 Middle East & Africa Levodopa API Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Levodopa API
10.3 Manufacturing Process Analysis of Levodopa API
10.4 Industry Chain Structure of Levodopa API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Levodopa API Distributors
11.3 Levodopa API Customer
12 World Forecast Review for Levodopa API by Geographic Region
12.1 Global Levodopa API Market Size Forecast by Region
12.1.1 Global Levodopa API Forecast by Region (2026-2031)
12.1.2 Global Levodopa API Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Levodopa API Forecast by Type (2026-2031)
12.7 Global Levodopa API Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Shandong Xinhua Pharmaceutical
13.1.1 Shandong Xinhua Pharmaceutical Company Information
13.1.2 Shandong Xinhua Pharmaceutical Levodopa API Product Portfolios and Specifications
13.1.3 Shandong Xinhua Pharmaceutical Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Shandong Xinhua Pharmaceutical Main Business Overview
13.1.5 Shandong Xinhua Pharmaceutical Latest Developments
13.2 Zhejiang Wild Wind Pharmaceutical
13.2.1 Zhejiang Wild Wind Pharmaceutical Company Information
13.2.2 Zhejiang Wild Wind Pharmaceutical Levodopa API Product Portfolios and Specifications
13.2.3 Zhejiang Wild Wind Pharmaceutical Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Zhejiang Wild Wind Pharmaceutical Main Business Overview
13.2.5 Zhejiang Wild Wind Pharmaceutical Latest Developments
13.3 Zhe JIANG HUA HAI Pharmaceutical
13.3.1 Zhe JIANG HUA HAI Pharmaceutical Company Information
13.3.2 Zhe JIANG HUA HAI Pharmaceutical Levodopa API Product Portfolios and Specifications
13.3.3 Zhe JIANG HUA HAI Pharmaceutical Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Zhe JIANG HUA HAI Pharmaceutical Main Business Overview
13.3.5 Zhe JIANG HUA HAI Pharmaceutical Latest Developments
13.4 Divi's Laboratories
13.4.1 Divi's Laboratories Company Information
13.4.2 Divi's Laboratories Levodopa API Product Portfolios and Specifications
13.4.3 Divi's Laboratories Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Divi's Laboratories Main Business Overview
13.4.5 Divi's Laboratories Latest Developments
13.5 Amino Sciences
13.5.1 Amino Sciences Company Information
13.5.2 Amino Sciences Levodopa API Product Portfolios and Specifications
13.5.3 Amino Sciences Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Amino Sciences Main Business Overview
13.5.5 Amino Sciences Latest Developments
13.6 Alfa Chemistry
13.6.1 Alfa Chemistry Company Information
13.6.2 Alfa Chemistry Levodopa API Product Portfolios and Specifications
13.6.3 Alfa Chemistry Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Alfa Chemistry Main Business Overview
13.6.5 Alfa Chemistry Latest Developments
13.7 Chuxiong Yunzhi Phytopharmaceutical
13.7.1 Chuxiong Yunzhi Phytopharmaceutical Company Information
13.7.2 Chuxiong Yunzhi Phytopharmaceutical Levodopa API Product Portfolios and Specifications
13.7.3 Chuxiong Yunzhi Phytopharmaceutical Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Chuxiong Yunzhi Phytopharmaceutical Main Business Overview
13.7.5 Chuxiong Yunzhi Phytopharmaceutical Latest Developments
13.8 Bei Jing Scrianen Pharmaceutical
13.8.1 Bei Jing Scrianen Pharmaceutical Company Information
13.8.2 Bei Jing Scrianen Pharmaceutical Levodopa API Product Portfolios and Specifications
13.8.3 Bei Jing Scrianen Pharmaceutical Levodopa API Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Bei Jing Scrianen Pharmaceutical Main Business Overview
13.8.5 Bei Jing Scrianen Pharmaceutical Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂